patient with a melanoma confirmed histologically/pathologically
indication for initiating treatment with anti-PD1 immunotherapy or anti-PD1 + anti-CTLA4
You may not be if
patient unable to read and/or write
inability to follow up with the patient during the study period
refusal to participate after a reflection period
medical contraindication to initiating immunotherapy (active autoimmune disease requiring systemic treatment in the past 2 years, active infection, etc.)
not affiliated with a social security system
patient under legal protection, guardianship, or curatorship
person participating in another study that includes an ongoing exclusion period
Clareo Health | Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
